EUCTR2009-011305-17-IT进行中（未招募）不适用
A randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas - ND
ABRAXIS BIOSCIENCE LLC AN INDIRECT SUBSIDIARY OF CELGENE CORPORATIO0 个研究点目标入组 842 人开始时间: 2011年9月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 842
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patient has definitive histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas. The definitive diagnosis of metastatic pancreatic adenocarcinoma will be made by integrating the histopathological data within the context of the clinical and radiographic data. Patients with islet cell neoplasms are excluded. 2. Initial diagnosis of metastatic disease must have occurred =6 weeks prior to randomization in the study. 3. Patient has one or more metastatic tumors measurable by CT scan (or MRI, if patient is allergic to CT contrast media). 4. Male or non-pregnant and non-lactating female, and =18 years of age. • If a female patient is of child-bearing potential, as evidenced by regular menstrual periods, she must have a negative serum pregnancy test (ß-hCG) documented 72 hours prior to the first administration of study drug. • If sexually active, the patient must agree to use contraception considered adequate and appropriate by the Investigator during the period of administration of study drug. In addition, male and female patients must utilize contraception after the end of treatment as recommended in the product's Summary of Product Characteristics or Prescribing Information provided in the study manual. 5. Patients must have received no previous radiotherapy, surgery, chemotherapy or investigational therapy for the treatment of metastatic disease. Prior treatment with 5-FU or gemcitabine administered as a radiation sensitizer in the adjuvant setting is allowed, provided at least 6 months have elapsed since completion of the last dose and no lingering toxicities are present. Patients having received cytotoxic doses of gemcitabine or any other chemotherapy in the adjuvant setting are not eligible for this study. 6. Patient has adequate biological parameters as demonstrated by the following blood counts at Baseline (obtained =14 days prior to randomization): • Absolute neutrophil count (ANC) =1.5 × 10^9/L; • Platelet count =100,000/mm3 (100 × 10^9/L); • Hemoglobin (Hgb) =9 g/dL. 7. Patient has the following blood chemistry levels at Baseline (obtained =14 days prior to randomization): • AST (SGOT), ALT (SGPT) =2.5 × upper limit of normal range (ULN), unless liver metastases are clearly present, then =5 × ULN is allowed • Total bilirubin =ULN • Serum creatinine within normal limits or calculated clearance =60 mL/min/1.73 m² for patients with serum creatinine levels above or below the institutional normal value. If using creatinine clearance, actual body weight should be used for calculating creatinine clearance (eg, using the Cockroft-Gault formula). For patients with a Body Mass Index (BMI) >30 kg/m², lean body weight should be used instead. 8. Patient has acceptable coagulation studies (obtained =14 days prior to randomization) as demonstrated by prothrombin time (PT) and partial thromboplastin time (PTT) within normal limits (±15%). 9. Patient has no clinically significant abnormalities in urinalysis results (obtained =14 days prior to randomization). 10. Patient has a Karnofsky performance status (KPS) = 70. Two observers will be required to assess KPS. If discrepant, the one with the lowest assessment will be considered true. 11. Patients should be asymptomatic for jaundice prior to Day 1. Significant or symptomatic amounts of ascites should be drained prior to Day 1. Pain symptoms should be stable and should not require modifications in analgesic managem
排除标准
- •1. Patient has known brain metastases, unless previously treated and well-controlled for at least 3 months (defined as clinically stable, no edema, no steroids and stable in 2 scans at least 4 weeks apart). 2. Patient has only locally advanced disease. 3. Patient has experienced a =10% decrease in KPS between Baseline visit and within 72 hours prior to randomization. 4. Patient has a =20% decrease in serum albumin level between Baseline visit and within 72 hours prior to randomization. 5. History of malignancy in the last 5 years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible. Patients with other malignancies are eligible if they were cured by surgery alone or surgery plus radiotherapy and have been continuously disease-free for at least 5 years. 6. Patient uses Coumadin. 7. Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy. 8. Patient has known historical or active infection with HIV, hepatitis B, or hepatitis C. 9. Patient has undergone major surgery, other than diagnostic surgery (ie, surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment in this study. 10. Patient has a history of allergy or hypersensitivity to any of the study drugs or any of their excipients, or the patient exhibits any of the events outlined in the Contraindications or Special Warnings and Precautions sections of the product or comparator SmPC or Prescribing Information. 11. History of connective tissue disorders (eg, lupus, scleroderma, arteritis nodosa). 12. Patients with a history of interstitial lung disease. 13. History of chronic leukemias (eg, chronic lymphocytic leukemia). 14. Patients with high cardiovascular risk, including, but not limited to, recent coronary stenting or myocardial infarction in the past year. 15. History of Peripheral Artery Disease (eg, claudication, Leo Buerger's disease). 16. Patient has serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the patient's safety or the study data integrity. 17. Patient is enrolled in any other clinical protocol or investigational trial. 18. Patient is unwilling or unable to comply with study procedures, or is planning to take vacation for 7 or more consecutive days during the course of the study.
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to find out whether ABI-007 given together with gemcitabine is as safe and effective as gemcitabine alone, in the treatment of patients with pancreatic cancer that has spread to other organs (metastatic adenocarcinoma of the pancreas)Metastatic Adenocarcinoma of the PancreasMedDRA version: 14.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-011305-17-ESAbraxis BioScience, LLC, an indirect subsidiary of Celgene Corporation842
进行中（未招募）
不适用
A clinical trial to find out whether ABI-007 given together with gemcitabine is as safe and effective as gemcitabine alone, in the treatment of patients with pancreatic cancer that has spread to other organs (metastatic adenocarcinoma of the pancreas)Metastatic Adenocarcinoma of the PancreasMedDRA version: 14.1Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2009-011305-17-DEAbraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation842
进行中（未招募）
不适用
A clinical trial to find out whether ABI-007 given together with gemcitabine is as safe and effective as gemcitabine alone, in the treatment of patients with pancreatic cancer that has spread to other organs (metastatic adenocarcinoma of the pancreas)Metastatic Adenocarcinoma of the PancreasMedDRA version: 14.1Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2009-011305-17-ATAbraxis BioScience, LLC, a wholly owned subsidiary of Celgene Corporation842
进行中（未招募）
1 期
A clinical trial to find out whether ABI-007 given together with gemcitabine is as safe and effective as gemcitabine alone, in the treatment of patients with pancreatic cancer that has spread to other organs (metastatic adenocarcinoma of the pancreas)EUCTR2009-011305-17-BEAbraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation842
进行中（未招募）
1 期
Efficacy of ABI-007 plus Gemcitabine or Simplified LV5FU2 as First-line Therapy in Patients with Metastatic Pancreatic Cancer.metastatic pancreatic cancerMedDRA version: 14.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864EUCTR2013-001463-23-FRGERCOR114